Online Inquiry
Castration-Resistant Prostate Cancer (CRPC)
Chemoresistant prostate cancer (CRPC) is an important stage in the progression of prostate cancer to an advanced stage, where it poses a direct threat to a person's life. At Alfa Cytology, our experts have been working on denervation-resistant prostate cancer (CRPC). With our extensive experience and advanced platforms, we offer you the best solutions.
Introduction to Castration-Resistant Prostate Cancer (CRPC)
Castration-resistant prostate cancer (CRPC) is a condition in which the cancer no longer responds to depotentized levels of testosterone alone, and progresses even after the patient receives treatment that significantly lowers testosterone levels. The emergence of CRPC means that prostate cancer is no longer solely dependent on androgens to sustain its growth. Traditionally, prostate cancer treatment has relied heavily on depot therapy. However, as the disease progresses, the cancer cells regain androgen dependence through various mechanisms and continue to grow even in the presence of very low androgen levels.
Fig. 1 Mechanisms of castration-resistant prostate cancer (CRPC). (Le, T. K., et al. 2023)
Research Priorities in Castration-Resistant Prostate Cancer (CRPC)
Mechanism Research
Understanding the molecular mechanisms of CRPC is at the center of research. Researchers have found that the development of CRPC involves a variety of biological processes, including alterations in the androgen receptor (AR) signaling pathway, genetic mutations within cancer cells, and adaptation of cancer cells to the environment. These mechanisms enable cancer cells to continue to survive and proliferate in a denuded environment.
New Drug Development
The development of new drugs targeting CRPC is accelerating. Currently, several novel drugs have shown some efficacy. For example, Abiraterone and Enzalutamide are drugs targeting the androgen receptor, which can effectively slow down the progression of CRPC patients. In addition, immunotherapy, targeted therapy and combination therapy have also become hot spots for research.
Individualized Therapy
Due to the complexity of CRPC, individualized treatment has become an important direction of research. Through the analysis of genomics and proteomics, the most suitable treatment plan can be formulated for an individual. This approach of precision medicine can improve the effectiveness of treatment and reduce unnecessary side effects.
Therapy Development in Castration-Resistant Prostate Cancer (CRPC)
| Name | Company | Country | Phase |
| ABBV-969 | AbbVie Inc. | USA | Phase I |
| HP518 | Hecen Pharma | China | Phase I/II |
| ARX517 | Ambrx Biopharma | USA | Phase I/II |
| HC-1119 | Hengrui Medicine Co., Ltd. | China | Phase III |
| Darolutamide | Bayer AG & Orion Corporation | Germany & Finland | Market Approval |
Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Hormone therapy initially controlled prostate cancer by suppressing AR signaling, but led to the development of castration-resistant prostate cancer (CRPC). It is now important to develop treatments that effectively target castration-resistant prostate cancer (CRPC). At Alfa Cytology, we are committed to providing one-stop therapy development platform in CRPC, with advanced technology and expertise.
One-Stop Solutions for Castration-Resistant Prostate Cancer (CRPC)
Offer complete development of small molecule inhibitors, from discovering lead compounds to enhancing their chemistry, screening, and adjusting them for better performance.
Provide all-in-one services for creating monoclonal antibodies, involving selecting B-cells, using hybridoma tech, purifying antibodies, and making further engineering tweaks.
Specific cells are modified, cultured and expanded, and finally the resulting cells are characterized to develop cellular drugs for the therapy of prostate cancer.
Provide synergistic effects of multiple therapeutic strategies including targeted therapy, immunotherapy, endocrine therapy, etc.
Additionally, we provide a wide range of in vitro and in vivo models to accelerate your drug development process.
We also offer comprehensive preclinical research services, including specialized experimental platforms for efficacy evaluation, DMPK/ADME and safety assessment.
If you are looking for therapy development services for castration-resistant prostate cancer, Alfa Cytology provides comprehensive support. By partnering with us, you'll receive personalized consulting services and efficient project advancement. If you are interested in our services, please don't hesitate to contact us for further information and pricing details.
Reference
- Le, T. K., et al. Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments. Cancers. 2023, 15(20): 5047.
For research use only.